Header
Header
Article

Left atrial late gadolinium enhancement in patients with ischaemic stroke



. 2023 Jan 24;jead008.


doi: 10.1093/ehjci/jead008.


Online ahead of print.

Affiliations

Item in Clipboard

Bjørn Strøier Larsen et al.


Eur Heart J Cardiovasc Imaging.


.

Abstract


Aims:

To evaluate the extent of left atrial (LA) fibrosis in patients with a recent stroke without atrial fibrillation and controls without established cardiovascular disease.


Methods and results:

This prospectively designed study used cardiac magnetic resonance to detect LA late gadolinium enhancement as a proxy for LA fibrosis. Between 2019 and 2021, we consecutively included 100 patients free of atrial fibrillation with recent ischaemic stroke (<30 days) and 50 age- and sex-matched controls. LA fibrosis assessment was achieved in 78 patients and 45 controls. Blinded to the cardiac magnetic resonance results, strokes were adjudicated according to modified Trial of Org 10172 in Acute Stroke Treatment classification as undetermined aetiology (n = 42) or as attributable to large- or small-vessel disease (n = 36). Patients with stroke had a larger extent of LA fibrosis [6.9%, interquartile range (IQR) 3.6-15.4%] than matched controls (4.2%, IQR 2.3-7.5%; P = 0.007). No differences in LA fibrosis were observed between patients with stroke of undetermined aetiology and those with large- or small-vessel disease (6.6%, IQR 3.8-16.0% vs. 6.9%, IQR 3.4-14.6%; P = 0.73).


Conclusion:

LA fibrosis was more extensive in patients with stroke than in age- and sex-matched controls. A similar extent of LA fibrosis was observed in patients with stroke of undetermined aetiology and stroke classified as attributable to large- or small-vessel disease. Our findings suggest that LA structural abnormality is more frequent in patients with stroke than in controls independent of aetiological classification.


Keywords:

atrial cardiomyopathy; atrial remodelling; cardiac magnetic resonance; ischaemic stroke.

Conflict of interest statement

Conflict of interest: H.C.: National Lead and steering committee member for Bayer (PACIFIC-STROKE and OCEANIC-STROKE) and Alexion (ANNEXA-i) Speaker honoraria: Bayer, Daiichi-Sankyo, BMS, and Boehringer. Senior guest editor: Stroke. All the other authors have no conflict of interest to disclose.



Source link

Back to top button